As China accelerates drug development and forging licensing deals at a speed few expected, U.S. biotech leaders are increasingly divided over what it means: a global opportunity to collaborate—or a structural challenge to American leadership.
At STAT Breakthrough East, a conference held on March 19, executives from Biogen and Bristol Myers Squibb, alongside academic leaders, framed China’s rise less as a direct threat and more as a force reshaping how innovation happens across borders.
“I’d like to think [China’s biotech rise] not as a threat, but an opportunity,” said Jane Grogan, executive vice president and head of research at Biogen. She noted that roughly 30% of global clinical trials are now conducted in China, approaching the United States’ share of about 35%.
China’s expanding talent base is another factor. The country produced roughly three times as many PhDs as the U.S. last year, underscoring a deep and growing pool of young and hungry scientific talent poised to drive innovation.
For multinational companies, that combination of scale and speed is opening new avenues for collaboration. Grogan said Biogen is actively engaging with venture capital firms, academic institutions, and startups in China to explore partnerships and co-development opportunities.
From a patient perspective, some executives argue that the globalization of innovation is ultimately beneficial. “Getting the best innovation from around the world is the best outcome,” said Robert Plenge, executive vice president and chief research officer at Bristol Myers Squibb.
The NJ-based company partnered for $90 million upfront with Shanghai-based Harbour Biomed to develop multi-specific antibodies.
Yet even as companies embrace these opportunities, China’s rise is introducing a more competitive dynamic—one that is beginning to reshape how and where new drugs are developed.
What distinguishes China’s biotech sector, executives and researchers said, is not just scale—but speed.
Across multiple therapeutic areas, Chinese companies are rapidly advancing drug candidates from early discovery into clinical development. While oncology remains a core focus, pipelines are expanding quickly into immunology and inflammation, and next-generation modalities such as bispecific antibodies.
That momentum is increasingly visible in cross-border dealmaking. In one recent example, Madrigal Pharmaceuticals signed a deal with Suzhou Ribo Life Sciences for up to six siRNA therapies targeting metabolic dysfunction-associated steatohepatitis, including a $60 million upfront payment.
More broadly, licensing activity into China has accelerated sharply: in the first two months of 2026 alone, 41 transactions were recorded, with average deal sizes rising 76%, according to data reported by the South China Morning Post.
Beyond biologics, China has also made significant strides in cell and gene therapy over the past 12 to 24 months, further broadening its innovation footprint.
For multinational pharmaceutical companies, the geographic origin of innovation may matter less than the outcome. But for academic researchers and domestic industry leaders, the implications are more complex.
“I would argue that’s a multinational pharmaceutical company doesn’t care which branch, Shanghai, Madrid, or Tokyo, the outcome comes from, “ noted Michael Sadelain, Director of Columbia Initiative in Cell Engineering and Therapy.
“But from an academic point of view, the U.S. biotech industry, we risk losing the practice, the edge, and the knowledge if we increasingly rely on innovation from elsewhere.”
That concern reflects a deeper anxiety.
The outsourcing of early-stage development or partnering too heavily abroad could erode the United States’ long-term leadership in biotech innovation. Sadelain pointed to investigator-initiated trials as one potential way to preserve domestic expertise, but acknowledged the competitive pressures are intensifying.
Those pressures are already shaping behavior across the industry. Katrine Bosley, board chair of Arrakis Therapeutics, said U.S. biotech companies—particularly younger firms—are becoming more guarded in how they share early-stage research. “In the past year, I’ve seen companies become much more reserved,” she said. “They’re operating in stealth mode, or even complete stealth mode.”
The shift suggests that China’s rise is not only accelerating the pace of global drug development but also changing how innovation is conducted and protected. As competition deepens, collaboration and caution are surprisingly unfolding in parallel.
The debate at the STAT conference underscored a broader reality: China is no longer just a player in biotech innovation; its speed, scale, and growing global reach are forcing a recalibration across the industry. For U.S. biotech, the question is no longer whether to engage—but how to compete without losing its edge.
#biotech #biosecurity #uschina #health #strategy #pharma #healthinnovation
